Patent ID: 7419968

Claim:
A method for screening for therapeutic agents for administration in combination with (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl L-alaninylphosphoramidate or (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl L-alaninyl monophosphate, comprising contacting the candidate therapeutic agent and (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl L-alaninylphosphoramidate or (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl monophosphate with a cancer cell selected from the group consisting of a breast cancer cell, a non-small cell lung cancer cell, a rectal cancer cell, a head and neck cancer cell, a stomach cancer cell, a pancreatic cancer cell, a colon cancer cell, a liver cancer cell, a gastric cancer cell, a skin cancer cell, a bone cancer cell, a bone marrow cancer cell, a testicular cancer cell, a brain cancer cell, a lung cancer cell, a prostate cancer cell and an ovarian cancer cell, and wherein said cell endogenously overexpresses, intracellular thymidylate synthase enzyme and assaying for cell death.